MYO16-AS1

Across TCGA pan-cancer cohorts, MYO16-AS1 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of MYO16-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where MYO16-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types MYO16-AS1 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

LUAD, LUSC, and HNSC are the cancer types where MYO16-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYO16-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	−2.912	<.001	9	view →
LUSC	Female	II,III,IV	−3.130	<.001	8	view →
HNSC	Male	All	+0.720	<.001	7	view →
COAD	All	All	+0.261	.001	6	view →
STAD	All	II,III,IV	+0.708	.022	3	view →
BLCA	All	All	+0.369	.025	2	view →
THCA	All	All	+0.179	.016	2	view →
KIRP	All	All	+0.105	.031	2	view →
KIRC	Male	All	+0.048	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

MYO16-AS1–LUAD

Open the LUAD breakdown →